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Surgical resection is the standard approach for patients with early stage 
NSCLC. Even after complete resection, about half of these patients will 
relapse and die within 5 years. Cisplatin-based adjuvant chemotherapy 
has been proven to improve the prognosis for patients with resected 
stages II, IIIA and perhaps some IB 1. In the LACE meta-analysis, the 
pooled hazard ratio was 0.89 (95% CI 0.82-0.96), translating into a 6% 
beneﬁt in 5-year survival (from 43 to 49%) with adjuvant chemother-
apy 2. Postoperative administration of Cisplatin-based chemotherapy, 
however, often results in substantial toxicity, especially after pneumo-
nectomy, and quite some patients are not able to receive it because of 
co-morbidity or postoperative problems 3. Effective and better tolerated 
adjuvant strategies are therefore most welcome.
Cancer immunotherapy might be a good candidate to achieve this goal. 
In a broad sense, cancer immunotherapy is stimulation of the immune 
system to treat cancer. This can be supportive (non-speciﬁc enhance-
ment of innate immune system), passive (supply immune response to 
the system by giving antibodies or cytotoxic T cells), or active by spe-
ciﬁc priming of the immune system to recognize the tumor as foreign. 
Only the last one is cancer vaccination in its true sense.
Conditions for optimal cancer vaccination are: 1/ speciﬁcity (i.e. hav-
ing a well deﬁned target antigen in the tumour, not in other tissues); 2/ 
selectivity (i.e. used in the population expressing the target); 3/ interac-
tion with antigen leads to (more) effective humoral and/or cellular 
response; 4/ tumour must be sensitive to immune killing in order to 
obtain improvement in patient outcome.
A recently reported phase II randomised study with postoperative 
vaccination with the MAGE-A3 vaccine in patients with completely 
resected non-small cell lung cancer (NSCLC) has to be seen in this 
perspective 4.
The postoperative MAGE-A3 approach meets quite some of the condi-
tions listed above. The MAGE-A3 gene is expressed speciﬁcally in 
tumour cells with no expression in normal cells (speciﬁcity). MAGE-
A3 is signiﬁcantly expressed in NSCLC, present in at least 35% of 
intra-operative samples in stages IB, II or IIIA tumours (selectivity) 
5. Pilot studies evaluating the MAGE-A3 cancer immunotherapeutic 
demonstrated humoral and cellular responses, and long-lasting clinical 
objective responses in metastatic melanoma patients 6,7. Moreover, the 
vaccine consists of the MAGE-A3 recombinant protein combined with 
a potent GSK proprietary immunological adjuvant. Therefore, post-
operative immunization with the MAGE-A3 cancer immunotherapeutic 
may be a tumor-speciﬁc, well tolerated, and effective adjuvant therapy.
In this phase II randomised study, patients with completely resected, 
MAGE-A3 positive, pathological stage IB or II NSCLC were randomly 
assigned to postoperative intramuscular administrations of MAGE-
A3 or placebo (2:1 randomisation), with 5 administrations at 3-week 
intervals, followed by 8 administrations every 3 months. Stratiﬁcation 
factors included stage (IB vs. II), histology (squamous carcinoma vs. 
other), and lymph-node procedure (minimal lymph-node sampling 
vs. radical mediastinal lymphadenectomy). The primary endpoint was 
disease-free interval; secondary endpoints were safety, disease-free 
survival, and overall survival.
A total of 1089 surgical tumour specimens were examined by rt-PCR, 
of which 363 expressed the MAGE-A3 gene. Between 01/2002 and 
05/2004, 182 patients (122 stage IB, 60 stage II) from 59 centres in 14 
European countries were randomised. The median age was 63 (45-81), 
87% were males, pathology was 65% squamous cell carcinoma. After a 
median follow-up of 28 months, 67 recurrences were observed. Group 
comparisons of disease-free interval, disease-free survival, and overall 
survival gave respectively a hazard ratio of 0.74 (95%CI 0.44-1.20, 
p=0.107), 0.73 (95%CI 0.45-1.16, p = 0.093) and 0.66 (95%CI 0.36-
1.20, p = 0.088) in favour of the MAGE-A3 group. Overall, treatment 
was well tolerated, with only 3 grade 3 adverse events possibly related 
to the treatment.
As whole, MAGE-A3 cancer immunotherapeutic as adjuvant treatment 
in completely resected Stage IB or II NSCLC was a targeted, well toler-
ated postoperative therapy, with a positive signal for clinical activity in 
the phase II randomised setting (relative improvement in disease-free 
interval and disease-free survival 27%). Further Phase III evaluation in 
early NSCLC is planned for 2007.
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Brain metastases are a common complication of advanced stage non-
small cell lung cancer (NSCLC), with an estimated incidence at initial 
diagnosis of 10-20%, increasing to up to 40% in the two years fol-
lowing diagnosis [Carolan 2005]. Palliative whole brain radiotherapy 
(WBRT) has been the mainstay of treatment for patients with multiple 
brain metastases, extending survival to 3-6 months. However, despite 
